相似文献
1
Six degrees of separation: the oxygen effect in the development of radiosensitizers.
Transl Oncol. 2011 Aug;4(4):189-98. doi: 10.1593/tlo.11166. Epub 2011 Aug 1.
2
Towards a Framework for Unifying Research in Theoretical Psychology.
Integr Psychol Behav Sci. 2024 Dec;58(4):1651-1667. doi: 10.1007/s12124-023-09790-z. Epub 2023 Jun 22.
3
The future of Cochrane Neonatal.
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
4
The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation.
Semin Oncol. 1992 Aug;19(4 Suppl 11):21-8.
5
Radiosensitizers, radioprotectors, and radiation mitigators.
Indian J Dent Res. 2014 Jan-Feb;25(1):83-90. doi: 10.4103/0970-9290.131142.
6
[Radiosensitization research in cancer therapy].
Gan To Kagaku Ryoho. 1985 Mar;12(3 Pt 1):405-11.
7
Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements.
Adv Drug Deliv Rev. 2017 Jan 15;109:84-101. doi: 10.1016/j.addr.2015.12.012. Epub 2015 Dec 19.
8
Gold Nanoparticles as Radiosensitizers in Cancer Radiotherapy.
Int J Nanomedicine. 2020 Nov 24;15:9407-9430. doi: 10.2147/IJN.S272902. eCollection 2020.
9
Radiosensitizers in the temozolomide era for newly diagnosed glioblastoma.
Neurooncol Pract. 2020 Jun;7(3):268-276. doi: 10.1093/nop/npz057. Epub 2019 Nov 30.
10
Chemical radiosensitization of hypoxic cells and redox potentials: correlation of voltammetric results with pulse radiolysis data of nitro-compounds and radiosensitizers.
Int J Radiat Biol Relat Stud Phys Chem Med. 1979 Jul;36(1):85-9. doi: 10.1080/09553007914550841.
引用本文的文献
1
Substituted benzylamino-2'-deoxyadenosine a modified nucleoside with radiosensitizing properties.
Sci Rep. 2025 May 20;15(1):17535. doi: 10.1038/s41598-025-99262-8.
2
Exploring the molecular mechanism of cancer radiosensitization: the impact of physical stimulation therapy.
Strahlenther Onkol. 2025 Mar 11. doi: 10.1007/s00066-025-02385-0.
3
Modeling of chemo-radiotherapy targeting growing vascular tumors: A continuum-level approach.
PLoS One. 2025 Jan 15;20(1):e0301657. doi: 10.1371/journal.pone.0301657. eCollection 2025.
4
Golden era of radiosensitizers.
Front Vet Sci. 2024 Dec 6;11:1450776. doi: 10.3389/fvets.2024.1450776. eCollection 2024.
5
Asymmetrically PEGylated and amphipathic heptamethine indocyanine dyes potentiate radiotherapy of renal cell carcinoma via mitochondrial targeting.
J Nanobiotechnology. 2024 Dec 18;22(1):756. doi: 10.1186/s12951-024-03012-3.
6
STING agonist-conjugated metal-organic framework induces artificial leukocytoid structures and immune hotspots for systemic antitumor responses.
Natl Sci Rev. 2024 May 10;11(7):nwae167. doi: 10.1093/nsr/nwae167. eCollection 2024 Jul.
7
Inhibition of LNC EBLN3P Enhances Radiation-Induced Mitochondrial Damage in Lung Cancer Cells by Targeting the Keap1/Nrf2/HO-1 Axis.
Biology (Basel). 2023 Sep 4;12(9):1208. doi: 10.3390/biology12091208.
8
Oxygen Imaging of a Rabbit Tumor Using a Human-Sized Pulse Electron Paramagnetic Resonance Imager.
Mol Imaging Biol. 2024 Jun;26(3):403-410. doi: 10.1007/s11307-023-01852-3. Epub 2023 Sep 15.
9
Innate Immune System in the Context of Radiation Therapy for Cancer.
Cancers (Basel). 2023 Aug 4;15(15):3972. doi: 10.3390/cancers15153972.
10
RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist.
Front Oncol. 2023 May 29;13:1204143. doi: 10.3389/fonc.2023.1204143. eCollection 2023.
本文引用的文献
1
Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials.
Cancer Res. 2012 May 15;72(10):2600-8. doi: 10.1158/0008-5472.CAN-11-2303.
2
Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.
Cancer Sci. 2011 Feb;102(2):324-9. doi: 10.1111/j.1349-7006.2010.01789.x. Epub 2010 Dec 10.
3
Dual role of NO donors in the reversal of tumor cell resistance and EMT: Downregulation of the NF-κB/Snail/YY1/RKIP circuitry.
Nitric Oxide. 2011 Jan 1;24(1):1-7. doi: 10.1016/j.niox.2010.10.001. Epub 2010 Oct 8.
4
Non-surgical care for locally advanced breast cancer: radiologically assessed therapeutic outcome of a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II) with systemic chemotherapy.
Oncol Rep. 2010 Nov;24(5):1161-8. doi: 10.3892/or_00000968.
5
Proteomic analysis of lanthanum citrate-induced apoptosis in human cervical carcinoma SiHa cells.
Biometals. 2010 Dec;23(6):1179-89. doi: 10.1007/s10534-010-9368-3. Epub 2010 Aug 1.
6
Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
Clin Cancer Res. 2010 Oct 15;16(20):4946-57. doi: 10.1158/1078-0432.CCR-10-1439. Epub 2010 Aug 20.
7
Inhibitors of angiogenesis: new hopes for oncologists, new challenges for anesthesiologists.
Anesthesiology. 2010 Sep;113(3):704-12. doi: 10.1097/ALN.0b013e3181ed098d.
8
Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer.
Mol Cancer Ther. 2010 Jul;9(7):2057-67. doi: 10.1158/1535-7163.MCT-09-0768. Epub 2010 Jun 29.
9
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.
Blood. 2010 Sep 2;116(9):1524-7. doi: 10.1182/blood-2010-02-269126. Epub 2010 Jun 7.
10
Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice.
J Thorac Oncol. 2010 Jul;5(7):940-9. doi: 10.1097/JTO.0b013e3181dc211f.
Zotero 插件